Compare Aon PLC (AON) vs Tempus AI (TEM) Price & Performance

AON trades at $356.94, up 0.39% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q1 2026 EPS of $6.48 beating expectations and revenue growth from $17.18B in 2025 to projected $17.5B in 2026. Net income margin improved to 22.54% with robust ROE of 46.82%. Recent news highlights dividend declarations and upcoming Q2 earnings.

AON presents a compelling investment case with consistent earnings beats, strong profitability metrics, and analyst consensus target of $399.67 offering 12% upside. Risks include elevated valuation multiples and debt levels, while institutional sentiment remains positive with 50% buy ratings. The stock's technical strength and fundamental growth support continued upward momentum.

Tempus AI (TEM) trades at $58.23, down 5.26% for the day, as the precision medicine technology company continues to show strong revenue growth but significant losses. The stock maintains a bullish technical signal with support at $58 and resistance at $64, while analysts remain optimistic with 61.5% buy ratings and a $63.50 consensus target. Recent FDA approvals for diagnostic tests and expanding AI platform capabilities provide growth catalysts despite ongoing operational losses.

The investment case hinges on Tempus's unique healthcare data platform and AI capabilities driving long-term growth, though substantial GAAP losses and negative cash flow from operations present near-term execution risks. With revenue projected to reach $1.4B in 2026 but net losses widening to $303M, the stock offers asymmetric upside if the company can achieve profitability while maintaining its 25%+ growth trajectory.